Denosumab is a monoclonal antibody that targets the RANK ligand and inhibits osteoclast activity, which may prove beneficial in breast cancer cases demonstrating dysregulated OPG/RANK/RANKL activity [58]. Here, TNFRSF11B is linked to breast carcinoma.